Unique Properties of Synaptosomes and Prospects for Their Use for the Treatment of Alzheimer’s Disease
- 1 June 2024
- journal article
- review article
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 89 (6) , 1031-1044
Abstract
Alzheimer’s disease (AD) is a severe neurodegenerative condition affecting millions worldwide. Prevalence of AD correlates with increased life expectancy and aging population in the developed countries. Considering that AD is a multifactorial disease involving various pathological processes such as synaptic dysfunction, neuroinflammation, oxidative stress, and improper protein folding, a comprehensive approach targeting multiple pathways may prove effective in slowing the disease progression. Cellular therapy and its further development in the form of cell vesicle and particularly mitochondrial transplantation represent promising approaches for treating neurodegeneration. The use of synaptosomes, due to uniqueness of their contents, could mark a new stage in the development of comprehensive therapies for neurodegenerative diseases, particularly AD. Synaptosomes contain unique memory mitochondria, which differ not only in size but also in functionality compared to the mitochondria in the neuronal soma. These synaptosomal mitochondria actively participate in cellular communication and signal transmission within synapses. Synaptosomes also contain other elements such as their own protein synthesis machinery, synaptic vesicles with neurotransmitters, synaptic adhesion molecules, and microRNAs – all crucial for synaptic transmission and, consequently, cognitive processes. Complex molecular ensemble ensures maintenance of the synaptic autonomy of mitochondria. Additionally, synaptosomes, with their affinity for neurons, can serve as an optimal platform for targeted drug delivery to nerve cells. This review discusses unique composition of synaptosomes, their capabilities and advantages, as well as limitations of their suggested use as therapeutic agents for treating neurodegenerative pathologies, particularly AD.Keywords
This publication has 114 references indexed in Scilit:
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Targeting the Meningeal Compartment to Resolve Chemobrain and Neuropathy via Nasal Delivery of Functionalized MitochondriaAdvanced Healthcare Materials, 2022
- Alzheimer's disease drug development pipeline: 2022Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- The extracellular vesicles‐derived from mesenchymal stromal cells: A new therapeutic option in regenerative medicineJournal of Cellular Biochemistry, 2018
- Synaptosomes2018
- AMP‐activated protein kinase mediates activity‐dependent axon branching by recruiting mitochondria to axonDevelopmental Neurobiology, 2013
- Stem cell technology for neurodegenerative diseasesAnnals of Neurology, 2011
- β‐Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodineJournal of Neuroscience Research, 2002
- The differential release of amino acids and neuropeptides from purified subpopulations of mammalian GABAergic and cholinergic cerebrocortical synaptosomesNeurochemical Research, 1993
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991